Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis

NCT00982488 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT00982488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00982488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
December 31, 2014
Enrollment
238 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia